Compare HMC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMC | RMD |
|---|---|---|
| Founded | 1946 | 1989 |
| Country | Japan | United States |
| Employees | 215320 | 10600 |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 29.4B |
| IPO Year | N/A | N/A |
| Metric | HMC | RMD |
|---|---|---|
| Price | $26.54 | $207.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $292.56 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.45% | 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.60 |
| Revenue Next Year | $4.36 | $7.41 |
| P/E Ratio | $40.40 | ★ $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.25 | $198.61 |
| 52 Week High | $34.89 | $293.81 |
| Indicator | HMC | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 43.72 |
| Support Level | $23.74 | $198.63 |
| Resistance Level | $26.66 | $260.21 |
| Average True Range (ATR) | 0.40 | 4.85 |
| MACD | 0.26 | 1.26 |
| Stochastic Oscillator | 94.59 | 62.06 |
Incorporated in 1948, Honda Motor was originally a motorcycle manufacturer. Today, the firm makes automobiles, motorcycles, and power products such as boat engines, generators, and lawnmowers. Including joint ventures, Honda sold 3.4 million light vehicles and 22.1 million motorcycles in fiscal 2026, and consolidated sales were JPY 21.8 trillion. Automobiles constitute 64% of revenue and motorcycles 18%, with the rest split between power products and financial services. Honda also makes robots and private jets.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.